Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Stotz SC"'
Autor:
Wasiak S; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Fu L; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Daze E; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Gilham D; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Rakai BD; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Stotz SC; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Tsujikawa LM; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Sarsons CD; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Studer D; Department of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada., Rinker KD; Department of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada., Jahagirdar R; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Wong NCW; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Sweeney M; Resverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA., Johansson JO; Resverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA., Kulikowski E; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Publikováno v:
Translational neuroscience [Transl Neurosci] 2023 Dec 31; Vol. 14 (1), pp. 20220332. Date of Electronic Publication: 2023 Dec 31 (Print Publication: 2023).
Autor:
Sarsons CD; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Gilham D; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Tsujikawa LM; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Wasiak S; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Fu L; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Rakai BD; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Stotz SC; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Carestia A; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Sweeney M; Resverlogix Corp., 535 Mission St., 14th Floor, San Francisco, CA 94105, USA., Kulikowski E; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada.
Publikováno v:
Biomedicines [Biomedicines] 2023 Sep 30; Vol. 11 (10). Date of Electronic Publication: 2023 Sep 30.
Autor:
Fu L; Resverlogix Corporation, Calgary, AB, Canada., Gilham D; Resverlogix Corporation, Calgary, AB, Canada., Stotz SC; Resverlogix Corporation, Calgary, AB, Canada., Sarsons CD; Resverlogix Corporation, Calgary, AB, Canada., Rakai BD; Resverlogix Corporation, Calgary, AB, Canada., Tsujikawa LM; Resverlogix Corporation, Calgary, AB, Canada., Wasiak S; Resverlogix Corporation, Calgary, AB, Canada., Johansson JO; Resverlogix Corporation, Calgary, AB, Canada., Sweeney M; Resverlogix Corporation, Calgary, AB, Canada., Wong NCW; Resverlogix Corporation, Calgary, AB, Canada., Kulikowski E; Resverlogix Corporation, Calgary, AB, Canada. Electronic address: ewelina@resverlogix.com.
Publikováno v:
International immunopharmacology [Int Immunopharmacol] 2023 Apr; Vol. 117, pp. 109929. Date of Electronic Publication: 2023 Feb 23.
Autor:
Wasiak S; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Tsujikawa LM; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Daze E; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Gilham D; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Stotz SC; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Rakai BD; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sarsons CD; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Fu L; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Azhar S; VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA., Jahagirdar R; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sweeney M; Resverlogix Inc., 535 Mission St, 14th Floor, San Francisco, CA, 94105., Johansson JO; Resverlogix Inc., 535 Mission St, 14th Floor, San Francisco, CA, 94105., Wong NCW; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Kulikowski E; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada. Electronic address: Ewelina@resverlogix.com.
Publikováno v:
Atherosclerosis [Atherosclerosis] 2023 Jan; Vol. 364, pp. 10-19. Date of Electronic Publication: 2022 Nov 23.
Autor:
Tsujikawa LM; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: laura@resverlogix.com., Kharenko OA; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: olesya@resverlogix.com., Stotz SC; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: sstotz@resverlogix.com., Rakai BD; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: bdrakai@gmail.com., Sarsons CD; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: chris@resverlogix.com., Gilham D; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: dean@resverlogix.com., Wasiak S; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: sylwia@resverlogix.com., Fu L; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: li@resverlogix.com., Sweeney M; Resverlogix Corporation, Suite 4010, 44 Montgomery Street, San Francisco, CA 94104, USA. Electronic address: msweeney@resverlogix.com., Johansson JO; Resverlogix Corporation, Suite 4010, 44 Montgomery Street, San Francisco, CA 94104, USA. Electronic address: jan@resverlogix.com., Wong NCW; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: norm@resverlogix.com., Kulikowski E; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: ewelina@resverlogix.com.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Aug; Vol. 152, pp. 113230. Date of Electronic Publication: 2022 Jun 07.
Autor:
Fu L; Resverlogix Corp, Calgary, AB, Canada., Wasiak S; Resverlogix Corp, Calgary, AB, Canada., Tsujikawa LM; Resverlogix Corp, Calgary, AB, Canada., Rakai BD; Resverlogix Corp, Calgary, AB, Canada., Stotz SC; Resverlogix Corp, Calgary, AB, Canada., Wong NCW; Resverlogix Corp, Calgary, AB, Canada., Johansson JO; Resverlogix Inc, San Francisco, California, USA., Sweeney M; Resverlogix Inc, San Francisco, California, USA., Mohan CM; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Khan A; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Metabolics and Genetics in Calgary (M.A.G.I.C.) Clinic Ltd., Calgary, AB, Canada., Kulikowski E; Resverlogix Corp, Calgary, AB, Canada.
Publikováno v:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Jun; Vol. 10 (3), pp. e00949.
Autor:
Gilham D; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Smith AL; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA., Fu L; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Moore DY; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA., Muralidharan A; Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA., Reid SPM; Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA., Stotz SC; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Johansson JO; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Sweeney M; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Wong NCW; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., Kulikowski E; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada., El-Gamal D; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 986805 NE Med Center, BCC 4.12.396, Omaha, NE 68198, USA.
Publikováno v:
Biomedicines [Biomedicines] 2021 Apr 18; Vol. 9 (4). Date of Electronic Publication: 2021 Apr 18.
Autor:
Wasiak S; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Dzobo KE; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Rakai BD; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Kaiser Y; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Versloot M; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Bahjat M; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Stotz SC; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Fu L; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sweeney M; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Johansson JO; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Wong NCW; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Stroes ESG; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Kroon J; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Kulikowski E; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada. Ewelina@resverlogix.com.
Publikováno v:
Clinical epigenetics [Clin Epigenetics] 2020 Nov 11; Vol. 12 (1), pp. 166. Date of Electronic Publication: 2020 Nov 11.
Autor:
Wasiak S; Resverlogix Corp., Calgary, AB, Canada., Gilham D; Resverlogix Corp., Calgary, AB, Canada., Daze E; Resverlogix Corp., Calgary, AB, Canada., Tsujikawa LM; Resverlogix Corp., Calgary, AB, Canada., Halliday C; Resverlogix Corp., Calgary, AB, Canada., Stotz SC; Resverlogix Corp., Calgary, AB, Canada., Rakai BD; Resverlogix Corp., Calgary, AB, Canada., Fu L; Resverlogix Corp., Calgary, AB, Canada., Jahagirdar R; Resverlogix Corp., Calgary, AB, Canada., Sweeney M; Resverlogix Inc., San Francisco, CA, USA., Johansson JO; Resverlogix Inc., San Francisco, CA, USA., Wong NCW; Resverlogix Corp., Calgary, AB, Canada., Kulikowski E; Resverlogix Corp., Calgary, AB, Canada.
Publikováno v:
Cardiovascular therapeutics [Cardiovasc Ther] 2020 Jul 21; Vol. 2020, pp. 9397109. Date of Electronic Publication: 2020 Jul 21 (Print Publication: 2020).
Autor:
Tsujikawa LM; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Fu L; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Das S; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Halliday C; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Rakai BD; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Stotz SC; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Sarsons CD; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Gilham D; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Daze E; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Wasiak S; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Studer D; Cellular and Molecular Bioengineering Research Lab, Libin Cardiovascular Institute of Alberta, University of Calgary, HMRB 358/361 3330 University Drive NW, Calgary, AB, T2N 4 N1, Canada., Rinker KD; Cellular and Molecular Bioengineering Research Lab, Libin Cardiovascular Institute of Alberta, University of Calgary, HMRB 358/361 3330 University Drive NW, Calgary, AB, T2N 4 N1, Canada., Sweeney M; Resverlogix Inc., Suite 4010, 44 Montgomery Street, San Francisco, CA, 94104, USA., Johansson JO; Resverlogix Inc., Suite 4010, 44 Montgomery Street, San Francisco, CA, 94104, USA., Wong NCW; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada., Kulikowski E; Resverlogix Corp., 300, 4820 Richard Road SW, Calgary, AB, T3E 6 L1, Canada. Ewelina@resverlogix.com.
Publikováno v:
Clinical epigenetics [Clin Epigenetics] 2019 Jul 12; Vol. 11 (1), pp. 102. Date of Electronic Publication: 2019 Jul 12.